Ruchit Patel


  • LPC, Commendation, Nottingham Law School, 2004
  • LLB, First Class Honours, University of Wales, Aberystwyth, 2002
  • JD, First Class Honours, Universität Würzburg, 2001


  • Ireland, Solicitor, 2016
  • England and Wales, Solicitor, 2006
  • German

Ruchit Patel


Ruchit Patel joined Ropes & Gray in October 2015 as an antitrust partner in the firm’s London office. Ruchit advises some of the largest companies in the world on matters before the European Commission, UK Competition and Markets Authority, UK sectoral regulators, UK High Court. He also has litigation experience before the UK Competition Appeal Tribunal.

Ruchit also has significant experience advising clients on antitrust law matters in Asia. His clients include technology, financial services, private equity, and healthcare companies, among others.

Ruchit is a member of the Law Society of England and Wales. Ruchit has been recognized by Who’s Who Legal: Competition as “a very experienced competition lawyer” who “focuses on strategy and results” and “is uniquely dedicated to ensuring his clients’ success.” Legal 500 also noted that Ruchit brings “an in-depth knowledge of Indian competition law.”


Notable matters in which Ruchit has been involved include:

  • Acting for Oakley Capital on the acquisition of TechInsights, a technology patent analysis business
  • Acting for Baring Private Equity Asia on its US$1.8 billion sale, alongside the Shanghai-based Bright Food Group, of British breakfast cereal brand Weetabix to U.S.-based cereal company, Post Holdings
  • Acting for Bain Capital on its purchase of a controlling stake in MKM, the UK’s largest independent builders’ merchant, from 3i and Lloyds Development Capital
  • Advised Baring Private Equity on the sale of Weetabix to Post Holdings, Inc. for $1.8 billion
  • Pfizer – Advised Pfizer on the sale of its Hospira Infusion Business to ICU Medical, valued at $1. billion
  • Pfizer/Medivation  Advised Pfizer on its nearly $14 billion acquisition of Medivation, Inc.
  • Medtronic/Heartware – Advised Medtronic in relation to the European aspects of an acquisition in the medical technology sector valued at over $1 billion
  • Symantec/Blue Coat – Advised Blue Coat on the European aspects of its sale to Symantec valued at over $4 billion
  • Advising Warburg Pincus and General Atlantic on the antitrust aspects of a range of investments
  • Medtronic/Covidien – Advised on EC and ROW aspects of Medtronic’s $43 billion acquisition of Covidien. Secured approvals from 13 jurisdictions and coordinated a single remedy globally
  • Biomet – Advised on the divestiture buyer (Biomet) on J&J’s $21.3 billion acquisition of Synthes
  • Assisted Merck on its animal health joint venture with Sanofi-Aventis (ultimately abandoned). Awarded GCR “Deal of the Year” in 2011 in recognition of its size and complexity
  • Abbott/Solvay – Advised Abbott on its $4.5 billion acquisition of Solvay’s pharmaceuticals and diagnostics business, which was conditionally cleared at Phase I
  • AkzoNobel/Metlac – Advised Metlac in defense of the Competition Commission’s decision to prohibit AkzoNobel’s acquisition of Metlac. This matter was named Legal Business’s “Competition Law Matter of the Year”
  • Western Digital/Hitachi – Advised Western Digital on its $4.5 billion bid. Obtained conditional clearance of a “3 to 2” transaction following Phase II review
  • Diageo/Mey – Advised TPG on Diageo’s acquisition of Mey, obtaining conditional clearance following a Phase II review


  • Assisting Google with several multi-jurisdictional competition law investigations
  • Credit Default Swaps – Represented a Wall Street dealer in the defense of allegations of collusion by the European Commission
  • DRAM – Assisted on settlement negotiations with the European Commission
  • IBM – Assisted IBM with a complaint to the European Commission in relation to “midrange” servers
  • Unannounced Inspections - Acted in relation to unannounced investigations in the construction industry, the airlines industry and in the retail sector. Acted on the European Commission’s second unannounced investigation under the EU Merger Regulation

Litigation & Counseling:

  • AkzoNobel/Metlac – Assisted Metlac in defence of the Competition Commission’s decision to prohibit AkzoNobel’s acquisition of Metlac
  • Celesio v. OFT – Acted on behalf of Boots plc in relation to Celesio’s appeal of the OFT’s decision in Boots/Alliance Unichem in the Competition Appeal Tribunal
  • National Grid v. Ofgem – Represented an intervener in relation to Ofgem’s decision to fine British Gas for exclusionary policy in relation to gas and electricity matters


  • Quoted, “Regulation is ‘greatest risk’ for PE managers,” Private Funds Management (September 29, 2017) 
  • Author, “The Development Of The European Commission’s Decisional Practice On Failing Division Defences,” World Competition, September 2015, (nominated for World Competition’s Legal Writing Award (Under 35 category))
  •  Author, “The Treatment of Late Filings in Indian Merger Control,” World Competition and Indian Lawyer, 2014
  • Co-author, “Dominance,” EC Competition Law Series, Volume V: Abuse of Dominance Under Article 102 TFEU, Claeys & Casteels, September 2013
  • Co-author, “Now the Commission Wants Damages Too… The Commission as Private Damages Claimant and Its Implications,” CPI Antitrust Chronicle, July 15, 2013 (nominated for Concurrences Legal Writing Award for Private Actions)
  • Author, “Barmi v. the Board of Control for Cricket in India: One to Send Upstairs?” Kluwer Competition Law Blog, February 2013
  • Author, “2013: The Wind of Change,” Competition Policy International, January 2013
  • Author, “BIS Reforms to the UK Merger Regime: An Opportunity Missed,” Competition Law Journal, Volume 11/Issue 2, 2012
  • Author, “The Removal of Dishonesty from the Cartel Offence and the Publication Defence: A Panacea?” CPI Antitrust Journal, Spring 2012
  • Author, “The Development of UK Jurisprudence on Hub and Spoke Cartels,” Global Competition Review, October 2010
  • Author, “The English Court of Appeal’s Judgment in Cooper Tire,” Competition Policy International, August 2010
  • Author, “Deliberate Concealment in Cartel Claims,” Competition Policy International, May 2010
  • Guest Editor, Competition Policy International Issue, May 2010
  • Author, “Oral Hearings and the Best Practices Guidelines,” Competition Policy International, March 2010


  • Speaker, “The Future of UK Merger Control – Mandatory vs Voluntary Notification and Other Issues: A Debate,” UK Competition Appeal Tribunal’s 6th Junior UK Competition Conference (January 27, 2012)


Ropes & Gray International LLP is a limited liability partnership registered in Delaware, United States of America and is a recognised body regulated by the Solicitors Regulation Authority (with registered number 52100).